Boiron SA (FR:BOI)
:BOI
Want to see FR:BOI full AI Analyst Report?
Top Page
Boiron SA
(BOI)
Select Model
Select Model
Rating:68Neutral
Price Target:
€28.00
▼(-7.89% Downside)
Action:ReiteratedDate:04/28/26
The score is driven primarily by solid underlying financial stability (notably low leverage) and attractive valuation (low P/E and strong dividend yield). These positives are partially offset by weak technicals (below major moving averages with negative MACD) and fundamental momentum concerns from inconsistent revenue and the severe reported 2025 revenue contraction alongside volatile free cash flow.
Positive Factors
Conservative balance sheet, low leverage
Sustained low leverage provides durable financial flexibility: it supports dividend policy, funds working capital, and cushions the business during demand shocks. A conservative balance sheet reduces refinancing risk and permits opportunistic investment without heavy interest burdens.
Negative Factors
Severe 2025 revenue contraction and choppy sales
A pronounced revenue collapse in 2025 and generally choppy top-line trends materially reduce earnings visibility and planning horizons. Persistent sales volatility can erode scale advantages, complicate inventory and supply decisions, and force margin trade-offs over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet, low leverage
Sustained low leverage provides durable financial flexibility: it supports dividend policy, funds working capital, and cushions the business during demand shocks. A conservative balance sheet reduces refinancing risk and permits opportunistic investment without heavy interest burdens.
Read all positive factors
Boiron SA (BOI) vs. iShares MSCI France ETF (EWQ)
Market Cap
€448.48M
Dividend Yield3.95%
Average Volume (3M)4.19K
Price to Earnings (P/E)16.3
Beta (1Y)0.23
Revenue Growth2.78%
EPS Growth187.96%
CountryFR
Employees2,469
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.21
Shares Outstanding17,545,408
10 Day Avg. Volume1,557
30 Day Avg. Volume4,187
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.35
Price to Sales (P/S)1.06
P/FCF Ratio17.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.06
Revenue Forecast (FY)€522.30M
Boiron SA Business Overview & Revenue Model
Company Description
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillo...
How the Company Makes Money
Boiron makes money primarily by selling homeopathic medicinal products under its own brands. Revenue is generated from (1) sales of finished over-the-counter (OTC) homeopathic products (e.g., single-ingredient and combination remedies) to pharmaci...
Boiron SA Financial Statement Overview
Summary
Income Statement
60
Neutral
Balance Sheet
82
Very Positive
Cash Flow
67
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 501.11M | 487.56M | 493.25M | 534.24M | 455.20M |
| Gross Profit | 365.73M | 358.76M | 358.08M | 379.73M | 327.62M |
| EBITDA | 66.30M | 45.46M | 73.67M | 91.33M | 78.75M |
| Net Income | 32.64M | 11.34M | 35.83M | 44.67M | 28.56M |
Balance Sheet | |||||
| Total Assets | 602.81M | 576.33M | 590.20M | 789.49M | 770.70M |
| Cash, Cash Equivalents and Short-Term Investments | 79.34M | 64.71M | 74.04M | 250.94M | 234.50M |
| Total Debt | 31.48M | 14.97M | 13.70M | 22.17M | 12.61M |
| Total Liabilities | 210.03M | 198.15M | 198.70M | 232.15M | 238.93M |
| Stockholders Equity | 392.76M | 378.14M | 393.66M | 557.62M | 531.74M |
Cash Flow | |||||
| Free Cash Flow | 29.72M | 33.77M | 27.47M | 41.51M | 13.46M |
| Operating Cash Flow | 53.24M | 42.17M | 45.49M | 60.10M | 33.88M |
| Investing Cash Flow | -23.39M | -18.36M | -22.93M | -15.28M | -11.92M |
| Financing Cash Flow | -24.39M | -27.85M | -198.41M | -28.99M | -22.00M |
Boiron SA Technical Analysis
Negative
30.40
Price Trends
27.06
Negative
28.50
Negative
26.55
Negative
Market Momentum
-0.31
Positive
34.76
Neutral
20.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BOI, the sentiment is Negative. The current price of 30.4 is above the 20-day moving average (MA) of 26.33, above the 50-day MA of 27.06, and above the 200-day MA of 26.55, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 34.76 is Neutral, neither overbought nor oversold. The STOCH value of 20.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:BOI.
Boiron SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | €448.48M | 16.29 | 5.18% | 3.95% | 2.78% | 187.96% | |
67 Neutral | €13.57B | 22.33 | 10.82% | 1.17% | 8.10% | 28.14% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
46 Neutral | €409.57M | -5.43 | -58.93% | ― | 3.00% | -1591.48% | |
45 Neutral | €977.36M | -3.62 | -241.12% | ― | ― | 13.91% | |
40 Neutral | €76.51M | -4.03 | ― | ― | -5.08% | -88.04% |
* General Sector Average
FR:BOI
Boiron SA
26.50
3.41
14.74%
FR:DBV
DBV Technologies
3.61
2.02
127.31%
FR:IPN
Ipsen
165.40
64.66
64.19%
FR:ALCOX
Nicox SA
0.40
0.17
71.74%
FR:VLA
Valneva
2.41
-0.47
-16.44%
FR:AB
AB Science SA
1.18
-0.25
-17.62%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.